Acumen Pharmaceuticals Inc. Common Stock (ABOS)
Stock · NASDAQ · Health Care
$1.69as of 10/16/2026
Price chart
Active signals
ABOS Signal Track Record
How signals performed across all stocks →What ABOS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 40 | -1.7% | 45% | September 18, 2026 |
| Bollinger Band Breakdown | 23 | -2.4% | 43% | September 16, 2026 |
| Bollinger Band Breakout | 24 | -0.5% | 50% | August 11, 2026 |
| 200-Day Moving Average TouchActive now | 13 | -12.4% | 31% | June 9, 2026 |
| Any 20-session window (baseline) | -4.8% | 42% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ABOS
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc.…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 60
- Website
- acumenpharm.com/
Fundamentals
- 1-day range
- $2$2.14
- Market cap
- $164.68M
- P/E (trailing)
- —
- P/E (forward)
- -1.41
- EPS (trailing)
- $-1.63
- Dividend yield
- —
- Beta
- 0.29
- Avg. volume
- 437.9K
Forecasts
5 analyst ratings
Acumen Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ABOSAcumen Pharmaceuticals Inc. Common Stock$1.69▲ 1.20%Market cap $164.68MP/E —$1.5$3.6
- LENZLENZ Therapeutics Inc. Common Stock$3.27▼ 8.40%Market cap $163.67MP/E —$3.35$42.98
- MOLNMolecular Partners AG American Depositary Shares$3.56▼ 2.47%Market cap $163.47MP/E —$2.66$3.96
- CRBUCaribou Biosciences Inc. Common Stock$0.47▲ 1.08%Market cap $162.66MP/E —$0.4425$3.54
- IPHAInnate Pharma S.A. ADS$1.43▼ 3.38%Market cap $167.42MP/E —$1.03$2.33
- HUMAHumacyte Inc. Common Stock$0.429▼ 2.50%Market cap $157.54MP/E —$0.337$1.9
- TNYATenaya Therapeutics Inc. Common Stock$0.381▼ 6.62%Market cap $157.50MP/E —$0.3601$2.04
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ABOS Acumen Pharmaceuticals Inc. Common Stock | $164.68M | — | $1.69 | ▲ 1.20% | $1.5$3.6 |
| LENZ LENZ Therapeutics Inc. Common Stock | $163.67M | — | $3.27 | ▼ 8.40% | $3.35$42.98 |
| MOLN Molecular Partners AG American Depositary Shares | $163.47M | — | $3.56 | ▼ 2.47% | $2.66$3.96 |
| CRBU Caribou Biosciences Inc. Common Stock | $162.66M | — | $0.47 | ▲ 1.08% | $0.4425$3.54 |
| IPHA Innate Pharma S.A. ADS | $167.42M | — | $1.43 | ▼ 3.38% | $1.03$2.33 |
| HUMA Humacyte Inc. Common Stock | $157.54M | — | $0.429 | ▼ 2.50% | $0.337$1.9 |
| TNYA Tenaya Therapeutics Inc. Common Stock | $157.50M | — | $0.381 | ▼ 6.62% | $0.3601$2.04 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- 4 Alzheimer's Drug Stocks to Watch on World Alzheimer's DayYahoo · 9/21/2026
- Acumen Pharmaceuticals, Inc. (ABOS) Analyst/Investor Day TranscriptSeekingAlpha · 9/16/2026
- BTIG Reiterates Buy on Acumen Pharmaceuticals, Maintains $8 Price TargetBenzinga · 9/16/2026
- Acumen Pharmaceuticals, Inc. (ABOS) Analyst/Investor Day - SlideshowSeekingAlpha · 9/16/2026
Insider Activity
Insider Actions →- Derrell Porter · June 17, 2026 · Option Exercise13.0K @ $1.07
- Derrell Porter · June 17, 2026 · Sale13.0K @ $2.33
- Derrell Porter · June 16, 2026 · Sale12.8K @ $2.33
- Derrell Porter · June 15, 2026 · Option Exercise6.5K @ $1.07
- Derrell Porter · June 15, 2026 · Sale6.5K @ $2.35
- Nathan B. Fountain · June 9, 2026 · Sale6.4K @ $2.23
- Nathan B. Fountain · June 3, 2026 · Grant53.3K
- Nathan B. Fountain · June 3, 2026 · Grant35.5K
- John A. Stalfort III · June 3, 2026 · Grant53.3K
- John A. Stalfort III · June 3, 2026 · Grant35.5K
- Derrell Porter · June 3, 2026 · Grant53.3K
- Derrell Porter · June 3, 2026 · Grant35.5K
- Jeffrey L. Ives · June 3, 2026 · Grant53.3K
- Jeffrey L. Ives · June 3, 2026 · Grant35.5K
- George Golumbeski · June 3, 2026 · Grant53.3K
Institutional Ownership
March 31, 2026
- Total shares held
- 45.96M
- Total value held
- $106.28M
- Institutional holders
- 82
- Unknown20.99M
- Unknown3.72M
- Unknown2.45M
- Unknown2.31M
- Unknown2.16M
- Unknown1.63M
- Unknown1.51M
- Unknown1.16M
- Unknown1.05M
- Unknown968.9K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Acumen Pharmaceuticals Featured in Alzheimer's Day Stock List
Acumen Pharmaceuticals was included in a Yahoo Finance article highlighting four Alzheimer's drug stocks to watch on World Alzheimer's Day. The mention serves as a reminder of the company's focus on neurodegenerative diseases, though the article does not report any new clinical data or corporate announcements. The stock is currently trading near its 52-week low, with an average analyst target of $7.60.
Acumen Pharmaceuticals Featured in Alzheimer's Day Stock List. Acumen Pharmaceuticals was included in a Yahoo Finance article highlighting four Alzheimer's drug stocks to watch on World Alzheimer's Day. The mention serves as a reminder of the company's focus on neurodegenerative diseases, though the article does not report any new clinical data or corporate announcements. The stock is currently trading near its 52-week low, with an average analyst target of $7.60.